New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
NCT ID NCT04550494
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times
Summary
This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study includes up to 36 participants with various cancers (breast, prostate, ovarian, pancreatic, gastric) and aims to see if the drug can shrink tumors or slow their growth, and whether taking different PARP inhibitors one after another might be beneficial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Talazoparib (a PARP inhibitor)
- What this could lead to
- If successful, this trial could show that talazoparib helps shrink or control advanced cancers with specific DNA repair defects, and may guide sequential use of different PARP inhibitors.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 36 participants. It focuses on biological markers rather than direct survival benefits, so results may not translate to widespread clinical use. Side effects of talazoparib include fatigue, nausea, and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Fasting during chemo: a new way to boost treatment?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Gut bacteria may fortify bones in breast cancer therapy